HIT vs OSCR vs HIMS vs CLOV vs TDOC

For growth investors, Health In Tech, Inc.

(HIT) is the stronger pick with 71. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Oscar Health, Inc. (OSCR) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hims & Hers Health, Inc.

(HIMS) is the cheapest at 50. 3x versus Health In Tech, Inc. at 78. 5x. On forward P/E, Oscar Health, Inc. is actually cheaper at 34. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Clover Health Investments, Corp.

(CLOV) is the lower-risk stock at 1. 22β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 97% more volatile than CLOV relative to the S&P 500. On balance sheet safety, Health In Tech, Inc. (HIT) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health In Tech, Inc.

(HIT) is pulling ahead at 71. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, HIT leads at 79. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -7. 9% for Teladoc Health, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Oscar Health, Inc.

(OSCR) trades at 34. 7x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 31. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 18. 1% to $3. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Clover Health Investments, Corp.

(CLOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Health In Tech, Inc. (HIT) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLOV: -72. 4%, HIT: -69. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HIT (Technology) and OSCR (Healthcare) and HIMS (Healthcare) and CLOV (Healthcare) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HIT is a small-cap high-growth stock; OSCR is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.